ArticleGut2021
Association between proton pump inhibitor use and gastric cancer: a population-based cohort study using two different types of nationwide databases in Korea.
Article in Gut, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 11 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 11 syntheses or guidelines pooled it, 96 citations in OpenAlex.
- Second Asian Consensus Report on Functional Dyspepsia (2025): Updated Recommendations.Journal of gastroenterology and hepatology · 2026Pooled it
- Association of Proton Pump Inhibitor Use With Gastric Cancer in Regions With High Prevalence of Gastric Cancer: Systematic Review and Meta-analysis.Journal of neurogastroenterology and motility · 2025Pooled it
- Proton pump inhibitors and the risk of gastric cancer: a systematic review, evidence synthesis and life course epidemiology perspective.BMJ open gastroenterology · 2025Pooled it
- Global status and trends of gastric cancer and gastric microbiota research: a bibliometric analysis.Frontiers in microbiology · 2024Pooled it
- Proton pump inhibitors and chronic kidney disease risk: a comparative study with histamine-2 receptor antagonists.Scientific reports · 2023Pooled it
- Gastric Cancer Risk in Patients with Long-Term Use of Proton Pump Inhibitors: A Systematic Review and Meta-Analysis of Observational and Interventional Studies.Digestive diseases and sciences · 2023Pooled it
- Proton pump inhibitor use: systematic review of global trends and practices.European journal of clinical pharmacology · 2023Pooled it
- Association of proton pump inhibitors with gastric and colorectal cancer risk: A systematic review and meta-analysis.Frontiers in pharmacology · 2023Pooled it
- Pooled it
- Impact of pitavastatin on new-onset diabetes mellitus compared to atorvastatin and rosuvastatin: a distributed network analysis of 10 real-world databases.Cardiovascular diabetology · 2022 · on this mapPooled it
- Aspirin, metformin, and statin use on the risk of gastric cancer: A nationwide population-based cohort study in Korea with systematic review and meta-analysis.Cancer medicine · 2022Pooled it
- Real-world performance of indobufen versus aspirin after percutaneous coronary intervention: insights from the ASPIRATION registry.BMC medicine · 2024Trial
- Long-Term Proton Pump Inhibitor Use and Gastric Cancer Risk: Interpreting Population-Based Evidence.Gut and liver · 2026Article
- Proton Pump Inhibitors and Gastric Cancer: A Large-Scale Propensity Score-Matched Analysis.Gut and liver · 2026Article
- Article
- Comparison of Cardiovascular Events in Patients Receiving Concomitant Clopidogrel and Proton Pump Inhibitors Classified by CYP2C19 Inhibitory Potency.Arteriosclerosis, thrombosis, and vascular biology · 2026Observational
- Endoscopic Examination and Long-Term Use of Proton Pump Inhibitors for Gastroesophageal Reflux Disease Treatment in Japan.Drug, healthcare and patient safety · 2026Article
- Proton pump inhibitor increases intestinal epithelial paracellular permeability via the p38-MAPK/NF-κB signaling pathway.Molecular biology reports · 2025Article
- Proton pump inhibitor use and cardiovascular risk, all-cause, and cardiovascular mortality across baseline eGFR categories: a longitudinal study.Renal failure · 2025Article
- Gastric Cancer after <italic>Helicobacter pylori</italic> Eradication: Characteristics, Diagnosis, and Management.Digestion · 2025Review
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe association between proton pump inhibitor (PPI) use and gastric cancer related to
designThis study analysed the original and common data model versions of the Korean National Health Insurance Service database from 2002 to 2013. We compared the incidence rates of gastric cancer after 1-year drug exposure, between new users of PPIs and other drugs excluding PPIs, by Cox proportional hazards model. We also analysed the incidence of gastric cancer among PPI users after
resultsThe analysis included 11 741 patients in matched PPI and non-PPI cohorts after large-scale propensity score matching. During a median follow-up of 4.3 years, PPI use was associated with a 2.37-fold increased incidence of gastric cancer (PPI≥30 days vs non-PPI; 118/51 813 person-years vs 40/49 729 person-years; HR 2.37, 95% CI 1.56 to 3.68, p=0.001). The incidence rates of gastric cancer showed an increasing trend parallel to the duration of PPI use. In
conclusionPPI use was associated with gastric cancer, regardless of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.